Prolight Diagnostics showcases breakthrough POC technology at the AACC Annual Scientific Meeting & Clinical Lab Expo
Prolight Diagnostics (“Prolight”) announced today that it will showcase the company’s digital single molecule counting Point-of-Care (POC) system, with high-sensitive troponin capabilities, at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Anaheim, CA, July 23–27. “For the first time we will showcase a concept of our point-of-care (POC) […]
Annual General Meeting of Prolight Diagnostics AB (publ) on 11 May 2023
The Annual General Meeting (AGM) of Prolight Diagnostics AB (publ) took place on 11 May 2023 in Lund. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdiagnostics.se. The AGM resolved in accordance with all of the motions presented in the notification of the AGM. Resolution regarding the adoption of […]
Annual report for 2022
Prolight Diagnostics AB (publ) announces that the annual report for 2022 is now available on the company’s website, https://prolightdiagnostics.se/en/investor-relations/financial-reports/ and in the attached appendix. For further information, please contact:Prolight Diagnostics AB (publ)E-mail: ub@prolightdiagnostics.seTelephone: +46 73 582 39 87Website: www.prolightdiagnostics.se/en/ About UsProlight Diagnostics, together with the subsidiary Psyros Diagnostics and technology partners, develops innovative and flexible […]
NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), corp. Reg. no. 556570-9499, (the ”Company”) are hereby notified of the Annual General Meeting to be held on Thursday 11 May 2023 at 2 p.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification of attendanceShareholders who wish to participate in the Annual General Meeting must:– […]
Prolight Diagnostics selects ITL (a G&H Company) to develop commercial instrument
Prolight Diagnostics (“Prolight”) today announces that it has selected Integrated Technologies Limited (“ITL”) to develop the commercial instrument for its point-of-care digital immunoassay system. This next stage of product development builds on the prototypes developed in-house at Prolight’s subsidiary Psyros Diagnostics (“Psyros”) and will ensure that the commercial instrument is state of the art and […]
Prolight Diagnostics Delivers on SBRI Healthcare Grant
Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has successfully completed the SBRI Healthcare phase 2 award, accelerating development of its unique digital immunoassay. Psyros received the SBRI Healthcare phase 2 grant of approximately 1 million GBP last year, requiring the completion of certain milestones. Psyros has now met or exceeded all […]
Annual General Meeting of Prolight Diagnostics AB (publ) on 20 May 2022
The Annual General Meeting (AGM) of Prolight Diagnostics AB (publ) took place on Friday 20 May 2022. The AGM was conducted by way of postal voting, without the physical presence of shareholders. Full information regarding the decisions of the AGM is available on the companys website, www.prolightdiagnostics.se. Resolution regarding the adoption of the income statement […]
